Assigned to AXSOME THERAPEUTICS, INC., New York, NY (US)
Filed by AXSOME THERAPEUTICS, INC., New York, NY (US)
Filed on Sep. 7, 2022, as Appl. No. 17/930,272.
Application 17/930,272 is a continuation in part of application No. 17/404,129, filed on Aug. 17, 2021, granted, now 11,471,464.
Application 17/404,129 is a continuation of application No. 17/205,936, filed on Mar. 18, 2021, granted, now 11,185,550, issued on Nov. 30, 2021.
Application 17/205,936 is a continuation in part of application No. 16/857,435, filed on Apr. 24, 2020, granted, now 10,987,358, issued on Apr. 27, 2021.
Application 16/857,435 is a continuation in part of application No. 16/513,612, filed on Jul. 16, 2019, granted, now 10,688,102, issued on Jun. 23, 2020.
Application 16/513,612 is a continuation in part of application No. PCT/US2018/032162, filed on May 10, 2018.
Application PCT/US2018/032162 is a continuation in part of application No. PCT/US2018/012433, filed on Jan. 4, 2018.
Application PCT/US2018/032162 is a continuation in part of application No. 17/930,272.
Application 17/930,272 is a continuation in part of application No. 17/547,676, filed on Dec. 10, 2021, abandoned.
Application 17/547,676 is a continuation of application No. 17/122,618, filed on Dec. 15, 2020, granted, now 11,219,626, issued on Jan. 11, 2022.
Application 17/122,618 is a continuation in part of application No. PCT/US2019/040495, filed on Jul. 3, 2019.
Claims priority of provisional application 62/536,466, filed on Jul. 25, 2017.
Claims priority of provisional application 62/526,884, filed on Jun. 29, 2017.
Claims priority of provisional application 62/802,198, filed on Feb. 6, 2019.
Claims priority of provisional application 62/803,756, filed on Feb. 11, 2019.
Claims priority of provisional application 62/835,613, filed on Apr. 18, 2019.
Claims priority of provisional application 62/846,311, filed on May 10, 2019.
Claims priority of provisional application 62/693,871, filed on Jul. 3, 2018.
Prior Publication US 2023/0016504 A1, Jan. 19, 2023
1. A method of treating migraine, comprising orally administering one tablet daily to a human being in need thereof, wherein the tablet comprises about 20 mg of meloxicam, or a molar equivalent amount of a salt form of meloxicam, and from about 10 mg to about 15 mg of rizatriptan, or a molar equivalent amount of a salt form of rizatriptan.